AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that its common stock has been added to the Nasdaq Biotechnology Index (NBI), effective prior to the market open on December 22.
The NBI is designed to track the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market that meet specific eligibility criteria, including minimum market capitalization, average daily trading volume and seasoning as a public company.
The index is calculated using a modified capitalization-weighted methodology, and constituents are selected annually each December.
Srinivas Rao, AtaiBeckley CEO, described 2025 as a “defining year” for the company, pointing to progress across its pipeline and corporate foundation.
“We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs toward late-stage development, deepened our leadership in next-generation mental health therapeutics through the strategic combination between atai Life Sciences and Beckley Psytech, and are looking forward to the corporate domiciliation to the US expected around year end,” Rao said.
“As we look ahead, AtaiBeckley is entering a pivotal phase and is well positioned to translate scientific leadership into long-term value for both patients and shareholders, as our recent addition to the NBI further validates.”
Shares of AtaiBeckley added 3.8% on Tuesday morning.